Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

On Wednesday, Lilly said Zepbound would be sold directly in Walmart pharmacies for $349 to $499 a month. Next year, Lilly is ...

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

The social-media company said it would “aggressively” raise spending to stay competitive in the artificial-intelligence arms ...

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong international demand for weight-loss drugs ...

This week's dividend activity included increased payouts from Visa ( V) and Marathon Petroleum ( MRC) as well as declarations ...

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...